De Paoli P: Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.Clin Diagn Lab Immunol 2001, 8(4):671-677.
Marchetti G, Franzetti F, Gori A: Partial immune reconstitution of highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?J Antimicrob Chemother 2005, 55(4):401-409.
Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA, Lane C: IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.Blood 2004, 104:775-780.
Kovacs JA, Lempicki RA, Sidorov I, Adelsberger JW, Sereti I, Sachau W, Nelly G, Metcalf JA, Davey RT, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Isaac HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC: Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.J Clin Invest 2005, 115:2139-2148.
Seriti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC: In vivo expansion of CD4+ CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients.J Clin Invest 2005, 115:1839-1847.
Markowitz N, Bebchuk JD, Abrams DI: Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.Clin Infect Dis 2003, 37(8):e115-20.
Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Massimo G, Mauro M, Mario C, Andrea G: Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.AIDS 2004, 18:211-216.
Alimonti JB, Ball TB, Fowke KR: Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.J Gen Virol 2003, 84:1649-1661.
Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, Paya CV: Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor.J Exp Med 1997, 185:55-64.
Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprech RM, Kupfer A: Apoptosis occurs predominantly in bystander cells and do not in productively infected cells of HIV- and SIV-infected lymph nodes.Nat Med 1995, 1:129-134.
Decrion A-Z, Varin A, Estavoyer J-M, Herbein G: CXCR4-mediated T cell apoptosis in human immunodeficiency virus infection.J Gen Virol 2004, 85:1471-1478.
Mueller YM, de Rosa SC, Hutton JA, Witek J, Roederer M, Altman JD, Katsikis PD: Increased CD95/Fas-induced apoptosis of HIV-specific CD8+ T cells.Immunity 2001, 15:871-882.
Tateyama M, Oyaizu N, McCloskey TW, Than S, Pahwa S: CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas/FasL death signaling pathway.Blood 2000, 96:195-202.
de Oliveira Pinto LM, Lecoeur H, Ledru E, Rapp C, Olivier P, Gougeon ML: Lack of control of T cell apoptosis under ART. Influence of therapy regimen in vivo and in vitro.AIDS 2002, 16:329-339.
Badley AD, Parato K, Cameron DW, Kravcik S, Phenix BN, Ashby D, Kumar A, Lynch DH, Tschopp J, Angel JB: Dynamic correlation of apoptosis and immune activation during treatment of HIV infection.Cell Death Differ 1999, 6:420-432.
Bento JM, Lopez M, Martin JC, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V: Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.AIDS Res Hum Retroviruses 2002, 18:1379-1388.
Hansjee N, Kaufmann GR, Strub C, Weber R, Battegay M, Erb P, Swiss HIV Cohort Study: Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes.J Acquir Immune Defic Syndr 2004, 36:671-677.
Lewis DE, NG Tang DS, Wang X, Kozinetz C: Costimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV.Clin Immunol 1999, 90:302-312.
Pandolfi F, Pierdominici M, Marziali M, Bernardi ML, Antonelli G, Galati V, D'Offizi G, Aiuti F, IRHAN Study Group: Low-dose IL-2 reduces lymphocyte apoptosis and increases naïve CD4 cells in HIV-1 patients treated with ART.Clin Immunol 2000, 94:153-159.
Caggiari L, Zanussi S, Bortolin MT, D'Andrea M, Nasti G, Simonelli C, Tirelli U, De Paoli P: Effects of therapy with highly active anti-retroviral therapy (ART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients.Clin Exp Immunol 2000, 120:101-6.
Dyrhol-Riise A, Ohlsson M, Skarstein K, Nygaard S, Olofsson J, Jonsson R, Asjo B: T Cell Proliferation and Apoptosis in HIV-1-Infected Lymphoid Tissue: Impact of Highly Active Antiretroviral Therapy.Clin Immunol 2001, 101:180-191.
Dupont WE: Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data.Cambridge University Press, New York, NY; 2002.
Seriti I, Herpin B, Metcalf J, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane CH: CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.AIDS 2001, 15:1765-1775.
Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi J: CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:332-340.
Mildvan E, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A: Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.J Infect Dis 2004, 189:1811-1820.
Grelli S, d'Ettorre G, Lauria F, Montella F, Di Traglia L, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A: Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients.JAC 2004, 53:494-500.
Paiardini M, Cervasi B, Galati D, Dominici S, Albrecht H, Sfacteria A, Magnani M, Silvestre G, Piedimonte G: Early correction of cell cycle perturbations predicts the immunological response to therapy in HIV-infected patients.AIDS 2004, 18:393-412.
Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson J, Verheggen R, Zeh D, Markowitz NP, Beirn T: Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts ≥ 300/mm3: CPCRA 059.JAIDS 2002, 29:221-231.
Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG: T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.J Infect Dis 2003, 187:1534-1543.
Pitrak DL, Bolanos J, Hershow R, Novak RM: Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis.AIDS 2001, 15:1317-1319.
Zou W, Foussat A, Capitant C, Durand-Gasselin I, Bouchet L, Galanaud P, Levy Y, Emilie D, ANRS-048 IL-2 Study Group: Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients.J Acquir Immune Defic Syndr 1999, 22:31.